Pharmacotherapy of atrial fibrillation in COVID-19 patients

Tomaszuk‐Kazberuk, Anna; Koziński, Marek; Domienik‐Karłowicz, Justyna; Jaguszewski, Miłosz; Darocha, Szymon; Wybraniec, Maciej T.; Dobrowolski, Piotr; Kupczyńska, Karolina; Michalski, Błażej; Wańha, Wojciech; Kapłon‐Cieślicka, Agnieszka

doi:10.5603/cj.a2021.0088

Cited by 12 publications

(12 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, maintaining the DOAC during admission was not associated with increased mortality. In this sense, some authors have also observed these findings of benefit from the use of DOACs in patients with COVID-19 infection who required hospital admission 22 .…”

Section: Discussionmentioning

confidence: 84%

Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry

Gómez

Pérez‐Belmonte²,

Rubio‐Rivas³

et al. 2022

Medicina Clínica (English Edition)

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 84%

Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry

Gómez

Pérez‐Belmonte²,

Rubio‐Rivas³

et al. 2022

Medicina Clínica (English Edition)

View full text Add to dashboard Cite

“…A recent meta-analysis showed that the prevalence of new-onset atrial fibrillation in hospitalized patients with COVID-19 was 7.4% [ 29 ]. LMWH can be suggested as the preferred anticoagulation regimen for hospitalized patients with COVID-19 and new-onset atrial fibrillation with a high CHA₂DS₂-VASc score, especially those with critical disease, mainly due to the abovementioned fewer interactions, whereas DOACs would be preferred for long-term anticoagulation afterwards [ 30 ]. A recent Good Practice Guidance Statement by the International Society on Thrombosis and Haemostasis (ISTH) also recommends LMWH as the anticoagulant of choice for hospitalized patients with COVID-19 [ 31 ].…”

Section: Results—key Questions and Practical Recommendationsmentioning

confidence: 99%

Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials

Kyriakoulis

Dimakakos

Kyriakoulis

et al. 2022

JCM

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has been shown to be strongly associated with increased risk for venous thromboembolism events (VTE) mainly in the inpatient but also in the outpatient setting. Pharmacologic thromboprophylaxis has been shown to offer significant benefits in terms of reducing not only VTE events but also mortality, especially in acutely ill patients with COVID-19. Although the main source of evidence is derived from observational studies with several limitations, thromboprophylaxis is currently recommended for all hospitalized patients with acceptable bleeding risk by all national and international guidelines. Recently, high quality data from randomized controlled trials (RCTs) further support the role of thromboprophylaxis and provide insights into the optimal thromboprophylaxis strategy. The aim of this statement is to systematically review all the available evidence derived from RCTs regarding thromboprophylaxis strategies in patients with COVID-19 in different settings (either inpatient or outpatient) and provide evidence-based guidance to practical questions in everyday clinical practice. Clinical questions accompanied by practical recommendations are provided based on data derived from 20 RCTs that were identified and included in the present study. Overall, the main conclusions are: (i) thromboprophylaxis should be administered in all hospitalized patients with COVID-19, (ii) an optimal dose of inpatient thromboprophylaxis is dependent upon the severity of COVID-19, (iii) thromboprophylaxis should be administered on an individualized basis in post-discharge patients with COVID-19 with high thrombotic risk, and (iv) thromboprophylaxis should not be routinely administered in outpatients. Changes regarding the dominant SARS-CoV-2 variants, the wide immunization status (increasing rates of vaccination and reinfections), and the availability of antiviral therapies and monoclonal antibodies might affect the characteristics of patients with COVID-19; thus, future studies will inform us about the thrombotic risk and the optimal therapeutic strategies for these patients.

show abstract

“…Sin embargo, el mantener el ACOD durante el ingreso no se asoció con un aumento de la mortalidad. En este sentido, algunos autores también han observado estos hallazgos de beneficio del empleo de ACOD en pacientes con infección por COVID-19 que requirieron ingreso hospitalario 22 .…”

Section: Discussionunclassified

Factores de riesgo de mortalidad en pacientes con infección por SARS-CoV-2 y fibrilación auricular: datos del registro SEMI-COVID-19

Gómez¹,

Pérez‐Belmonte²,

Rubio‐Rivas³

et al. 2022

Medicina Clínica

View full text Add to dashboard Cite

Pharmacotherapy of atrial fibrillation in COVID-19 patients

Cited by 12 publications

References 31 publications

Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry

Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry

Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials

Factores de riesgo de mortalidad en pacientes con infección por SARS-CoV-2 y fibrilación auricular: datos del registro SEMI-COVID-19

Contact Info

Product

Resources

About